FPHAX Mutual Fund

NAV$31.09

Fund Essentials - as of Nov 30, 2025

Net Assets
$703M
Expense Ratio
0.67%
Dividend Yield (Current)
2.94%
Holdings
59
Inception Date
Jun 18, 2001
Fund Family
Fidelity Investments (US)
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Semi-Annually

Performance

YTD+7.66%
1 Year+27.67%
3 Year+23.63%
5 Year+15.07%
10 Year+12.69%

Asset Allocation

Stocks: 95.41%
Bonds: 0.16%
Cash: 4.43%

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co25.96%
AZN:LNAstraZeneca PLC11.19%
JNJJohnson & Johnson5.42%
MRKMerck & Company Inc5.04%
GSKGlaxosmithkline Finance Plc4.89%
Top 10 Concentration: 72.45%Report Date: Nov 30, 2025
Download all 59 holdings for FPHAX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
2.94%
Frequency
Semi-Annually

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

FPHAX Mutual Fund Overview

FPHAX Mutual Fund (Fidelity Select Pharmaceuticals Portfolio) is managed by Fidelity Investments (US) with $702.6M in net assets. FPHAX expense ratio is 0.67%, holding 59 positions across sectors including Health Care, Unknown, Financials. Inception date: 2001-06-18.

FPHAX performance shows a YTD return of 7.66%. The 1-year return is 27.67% and the 5-year return is 15.07%. FPHAX dividend yield stands at 2.94%, paid semi-annually.

FPHAX top holdings include Eli Lilly & Co (26.0%), AstraZeneca PLC (11.2%), Johnson & Johnson (5.4%), Merck & Company Inc (5.0%), Glaxosmithkline Finance Plc (4.9%). View all FPHAX holdings, sector breakdown, or dividend history.

FPHAX can be compared against other funds using the overlap calculator or side-by-side comparison tool. FPHAX alternatives are available via the screener, along with tax-loss harvesting opportunities.